MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer DOI Creative Commons

Suyeon Kim,

Ki Wook Lee,

Yongjin Yoo

et al.

Animal Cells and Systems, Journal Year: 2024, Volume and Issue: 28(1), P. 184 - 197

Published: April 30, 2024

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has chemotherapeutic potential as a regulator of an extrinsic apoptotic ligand, but its effect drug is limited by innate and acquired resistance. Recent findings suggest that intermediate tolerance could mediate resistance, which made the main obstacle for utility TRAIL anti-cancer therapeutics. We propose miRNA-dependent epigenetic modification drives tolerant state in TRAIL-induced (TDT). Transcriptomic analysis revealed

Language: Английский

Mitochondrial signaling pathways and their role in cancer drug resistance DOI
Ashwani Sharma, Tarun Virmani, Girish Kumar

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 122, P. 111329 - 111329

Published: Aug. 5, 2024

Language: Английский

Citations

7
Low toxicity ginsenoside Rg1-carbon nanodots as a potential therapeutic agent for human non-small cell lung cancer DOI
Jifeng Wang, Ning Tian, Tenghui Tian

et al.

Colloids and Surfaces B Biointerfaces, Journal Year: 2024, Volume and Issue: 246, P. 114392 - 114392

Published: Nov. 20, 2024

Language: Английский

Citations

4
Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance DOI

Guimei Li,

Meng Wang, Li Luo

et al.

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 285, P. 117249 - 117249

Published: Jan. 9, 2025

Language: Английский

Citations

0
Carbon nanodots derived from herbal extract ginsenoside Rg1 demonstrate highly effective inhibition against cervical carcinoma DOI
Jiahui Bao,

Xuechun Zhou,

Xiaoyu He

et al.

Carbon letters, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

Language: Английский

Citations

0
Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance DOI
Meng Wang,

Guimei Li,

Nan Xu

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 20, 2025

Acquired resistance in cancer remains a significant challenge oncology, posing obstacles to the efficacy of diverse therapeutic approaches. The nuclear factor-kappa B (NF-κB) signaling pathway plays an important role development drug tumor cells. Herein, we employed NF-κB inhibitors and cisplatin synthesize multitarget Pt(IV) antitumor prodrugs. Among them, antiproliferation activity complex 8 demonstrated remarkable 146.92-time increase compared against A549/CDDP Moreover, could effectively induce DNA damage, promote ROS generation, autophagy, trigger mitochondrial apoptosis pathway, suppress cell proliferation through pathway. Furthermore, downregulated levels VEGF HIF-1α exerted antiproliferative PI3K/AKT STAT-3 Interestingly, showed superior vivo than cisplatin, 5a, or their combination, suggesting its potential as promising candidate for further lung treatment.

Language: Английский

Citations

0
Investigating the antimicrobial activity of 1-heteroaryl benzotriazole silver compounds DOI Creative Commons

Ahmed Elzein,

Ghadah Abdullah S. Al Jomeh,

Graham J. Tizzard

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(15), P. 11431 - 11440

Published: Jan. 1, 2025

Five (1-5) Ag(i) compounds, derived from different N,N'-bidentate 1-heteroaryl benzotriazole ligands, were synthesised and characterised using SXRD, IR, UV-Vis, elemental analysis, ESI-MS, NMR. Variations in ligands counter-anions produced distinct structures morphologies. Preliminary antimicrobial testing at the micromolar level, DMSO, revealed that only compound 2, based on 1-(2-pyridyl)benzotriazole triflate anion, exhibited interesting properties, thus marking introduction of a new class compounds medicinal inorganic chemistry.

Language: Английский

Citations

0
DNA or Not DNA —That is the Question Determining the Design of Platinum Anticancer Drugs DOI
S. Jin,

Chenyao Feng,

Xiaoyong Wang

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 282, P. 117077 - 117077

Published: Nov. 17, 2024

Language: Английский

Citations

1
MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer DOI Creative Commons

Suyeon Kim,

Ki Wook Lee,

Yongjin Yoo

et al.

Animal Cells and Systems, Journal Year: 2024, Volume and Issue: 28(1), P. 184 - 197

Published: April 30, 2024

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has chemotherapeutic potential as a regulator of an extrinsic apoptotic ligand, but its effect drug is limited by innate and acquired resistance. Recent findings suggest that intermediate tolerance could mediate resistance, which made the main obstacle for utility TRAIL anti-cancer therapeutics. We propose miRNA-dependent epigenetic modification drives tolerant state in TRAIL-induced (TDT). Transcriptomic analysis revealed

Language: Английский

Citations

0